E-LIB Suche - Ergebnisse für: Blauvelt, A

1

Optimizing maintenance therapy in responders to abrocitinib..:

Thyssen, J. P. ; Silverberg, J. I. ; Ruano, J....
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

2

P1081 Pharmacokinetics and immunogenicity of the ustekinuma..:

Chow, V ; Mytych, D T ; Blauvelt, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1943-i1943 , 2024

Link: https://doi.org/10.1093/..

3

CO230 Efficacy and Safety of Roflumilast Foam 0.3% in Patie..:

Blauvelt, A. ; Draelos, Z.D. ; Gooderham, M....
Value in Health. 26 (2023) 6 - p. S59 , 2023

Link: https://doi.org/10.1016/..

4

ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: P..:

Eichenfield, L. ; Boguniewicz, M. ; Simpson, E....
Annals of Allergy, Asthma & Immunology. 131 (2023) 5 - p. S91 , 2023

Link: https://doi.org/10.1016/..

5

RUXOLITINIB CREAM DEMONSTRATES DURABLE LONG-TERM DISEASE CO..:

Geng, B. ; Eichenfield, L. ; Kircik, L....
Annals of Allergy, Asthma & Immunology. 131 (2023) 5 - p. S13 , 2023

Link: https://doi.org/10.1016/..

6

Efficacité de l'upadacitinib versus dupilumab dans la derma..:

Blauvelt, A. ; Silverberg, J.I. ; Eyerich, K....
Revue Française d'Allergologie. 63 (2023) 3 - p. 103606 , 2023

Link: https://doi.org/10.1016/..

7

Bimekizumab speed of response in patients with moderate to ..:

Blauvelt, A ; Duffin, KC ; Magnolo, N...
SKIN The Journal of Cutaneous Medicine. 6 (2022) 6 - p. s69 , 2022

Link: https://doi.org/10.25251..

8

LONG-TERM SAFETY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC D..:

Blauvelt, A. ; Eichenfield, L. ; Sierka, D....
Annals of Allergy, Asthma & Immunology. 129 (2022) 5 - p. S19 , 2022

Link: https://doi.org/10.1016/..

9

MEANINGFUL RESPONSES IN TRALOKINUMAB-TREATED ADOLESCENTS WI..:

Paller, A. ; Blauvelt, A. ; Soong, W....
Annals of Allergy, Asthma & Immunology. 129 (2022) 5 - p. S74 , 2022

Link: https://doi.org/10.1016/..

10

Dupilumab provides long-term efficacy for up to 4 years in ..:

Blauvelt, A. ; Thyssen, J.P. ; Lockshin, B....
Revue Française d'Allergologie. 62 (2022) 3 - p. 321 , 2022

Link: https://doi.org/10.1016/..

11

Super‐response to guselkumab treatment in patients with mod..:

Reich, K. ; Gordon, K.B. ; Strober, B....
Journal of the European Academy of Dermatology and Venereology. 36 (2022) 12 - p. 2393-2400 , 2022

Link: https://doi.org/10.1111/..

12

Maintenance of bimekizumab efficacy through 2 years in pati..:

Thaçi, D ; Armstrong, A ; Lebwohl, M...
SKIN The Journal of Cutaneous Medicine. 6 (2022) 6 - p. s71 , 2022

Link: https://doi.org/10.25251..

13

Durability of DLQI Improvements Among Patients with Moderat..:

Blauvelt, A ; Warren, RB ; Reich, K...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s19 , 2021

Link: https://doi.org/10.25251..

14

Bimekizumab Efficacy and Safety versus Adalimumab in Patien..:

Warren, RB ; Blauvelt, A ; Bagel, J...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s15 , 2021

Link: https://doi.org/10.25251..

15

Long-Term Improvements in Health-Related Quality of Life of..:

Thaçi, D ; Blauvelt, A ; Reich, K...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s20 , 2021

Link: https://doi.org/10.25251..